- Home
- Metabolic Research
Metabolic Research
Midnight Sun Peptides offers a curated selection of metabolic research peptides for laboratory and controlled scientific research use. This category brings together GLP receptor agonist compounds and novel metabolic signaling peptides that are actively studied in preclinical and clinical research environments worldwide.
Research Peptides — GLP Receptor Compounds
Our metabolic research peptide collection includes GLP-2T (a dual GIP/GLP-1 receptor agonist analog), GLP-3R (a triple GIP/GLP-1/glucagon receptor agonist based on retatrutide), CAGRI (an amylin receptor research compound based on cagrilintide), 5-Amino-1MQ (an NNMT enzyme inhibitor), and SLU-PP-332 (an ERR alpha agonist). Each compound represents a distinct receptor pathway or metabolic signaling mechanism under investigation in laboratory settings.
Every peptide in this category is independently third-party tested to greater than 99% purity using HPLC and mass spectrometry. Batch-specific Certificates of Analysis are published with every product — not generic documentation, but the actual laboratory report for your specific production lot. All metabolic research peptides are sold strictly for research use only and are not approved for human or veterinary use.
GLP Receptor Agonist Peptides for Metabolic Signaling Research
The glucagon-like peptide (GLP) receptor family represents one of the most intensively researched areas in contemporary metabolic science. GLP-1, GIP, and glucagon receptors are expressed across multiple tissues involved in glucose homeostasis, appetite regulation, and energy expenditure. Research-grade GLP receptor agonist peptides allow laboratory scientists to study these signaling pathways in controlled experimental models.
GLP receptor research peptides are classified by the number of receptor targets they engage. Single-agonist compounds target one receptor; dual-agonist compounds like tirzepatide engage two; triple-agonist compounds like retatrutide engage three simultaneously. Each additional receptor target introduces new metabolic signaling dimensions for researchers to investigate. Midnight Sun Peptides stocks compounds representing both dual and triple receptor agonist research categories.
GLP-2T (Tirzepatide Analog)
— Dual GIP/GLP-1 Receptor Research
GLP-2T is a research-grade analog based on tirzepatide — a synthetic 39-amino acid peptide that simultaneously engages both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). In laboratory research settings, dual GIP/GLP-1 receptor agonism is studied for its effects on incretin signaling pathways and receptor cross-talk mechanisms.
The dual-receptor engagement of GLP-2T makes it a useful research tool for scientists studying the interplay between GIP-mediated insulin potentiation and GLP-1-mediated gastric signaling. Research applications include receptor binding affinity studies, downstream signaling cascade analysis, and comparative receptor pharmacology in cell-based or animal models. GLP-2T is available in 20mg and 40mg individual vials, and in 10-vial bulk kits for larger research protocols requiring consistent compound supply.
Available sizes:
- 20mg
- 40mg
- 20mg ×10 Vials
- 40mg ×10 Vials
GLP-3R (Retatrutide)
— Triple Receptor Agonist Research Compound
GLP-3R is a research-grade compound based on retatrutide (LY3437943) — a next-generation synthetic peptide engineered to simultaneously activate three distinct metabolic hormone receptors: the GIP receptor (GIPR), the GLP-1 receptor (GLP-1R), and the glucagon receptor (GCGR). This triple-receptor activity is what distinguishes retatrutide-class compounds from earlier incretin-based peptides and makes GLP-3R one of the most closely studied metabolic research compounds currently available.
In laboratory research contexts, the addition of glucagon receptor activation to dual-incretin signaling introduces a third pathway dimension not present in single or dual agonist compounds. The GCGR component is associated with energy expenditure signaling and fat oxidation pathways — mechanisms distinct from the appetite and insulin signaling effects mediated by GLP-1R and GIPR. Researchers studying multi-receptor metabolic signaling, receptor selectivity, or compound potency comparisons will find GLP-3R a valuable addition to their research compound library.
GLP-3R (Retatrutide) is available in four individual sizes and corresponding 10-vial bulk kits, making it suitable for both small-scale pilot studies and extended research protocols.
Available sizes:
- 10mg
- 20mg
- 30mg
- 50mg
- All sizes in ×10 Vial kits
CAGRI (Cagrilintide)
— Amylin Receptor Research Peptide
CAGRI is a research-grade compound based on cagrilintide — a long-acting synthetic amylin analog developed by Novo Nordisk and currently under investigation in multiple clinical trial programs. Unlike GLP receptor agonists, cagrilintide targets the amylin receptor (AMY1-3), which mediates a distinct satiety signaling pathway involving post-meal fullness signals from pancreatic amylin secretion.
In research settings, amylin receptor agonism is studied as a complementary pathway to GLP-1 receptor-mediated signaling. The combination of amylin and incretin receptor activation has been investigated in clinical programs (including CagriSema) for its potential additive effects on appetite suppression and metabolic regulation. CAGRI is therefore of significant research interest for scientists studying receptor pathway complementarity, satiety signaling mechanisms, and multi-pathway metabolic research models.
Available sizes:
- CAGRI 10mg
5-Amino-1MQ & SLU-PP-332 — Novel Metabolic Research Compounds
Beyond GLP receptor agonists, this category includes two novel metabolic research compounds targeting distinct enzymatic and receptor pathways that have attracted growing scientific attention.
5-Amino-1MQ (NNMT Inhibitor)
5-Amino-1MQ is a small-molecule inhibitor of Nicotinamide N-Methyltransferase (NNMT) — an enzyme involved in NAD+ metabolism and cellular energy regulation. NNMT is expressed in adipose tissue and has been studied in the context of metabolic pathway regulation and energy homeostasis. Laboratory research with 5-Amino-1MQ focuses on NNMT enzyme inhibition kinetics, downstream effects on NAD+ availability, and cellular metabolic signaling in adipocyte and hepatic research models. Available as a 50mg lyophilized research compound.
Available sizes:
- 5-Amino-1MQ 50mg
SLU-PP-332 (ERR Alpha Agonist)
Available sizes:
- SLU-PP-332 (confirm size with team)
Why Purity Matters in Metabolic Peptide Research
Metabolic receptor research requires compound purity that reflects actual laboratory-grade standards — not marketing claims. Impure compounds introduce confounding variables into receptor binding studies, signaling cascade analysis, and dose-response experiments. A compound tested at 85% purity is not the same research tool as one verified at 99.4% purity by independent HPLC analysis.
Every metabolic research peptide sold by Midnight Sun Peptides is independently tested by an accredited third-party laboratory. Testing includes:
- HPLC Purity Analysis — confirms the percentage of target compound in the sample
- Mass Spectrometry Identity Confirmation — verifies the compound is correctly identified
- Batch-Specific COA — the actual test result for your production lot, not a template
Frequently Asked Questions
What is the difference between GLP-2T and GLP-3R?
GLP-2T is a research analog of tirzepatide — a dual receptor agonist that targets both the GIP receptor and the GLP-1 receptor simultaneously. GLP-3R is based on retatrutide, which adds a third receptor target — the glucagon receptor (GCGR) — on top of the dual GIP/GLP-1 engagement. In laboratory research terms, GLP-3R represents a triple-agonist mechanism while GLP-2T represents a dual-agonist mechanism. Researchers studying receptor selectivity, pathway specificity, or comparative agonism would use both to examine how each additional receptor target changes downstream signaling outcomes.
What is CAGRI and how does it differ from GLP receptor peptides?
CAGRI is a research compound based on cagrilintide, which targets the amylin receptor — a completely separate receptor system from the GLP-1, GIP, or glucagon receptors targeted by GLP-class peptides. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells and plays a distinct role in post-meal satiety signaling. In research contexts, CAGRI allows scientists to study amylin receptor biology independently, or to investigate combined amylin/incretin signaling when used alongside GLP-class compounds in multi-compound research protocols.
What purity level are these metabolic research peptides?
All metabolic research peptides carried by Midnight Sun Peptides are independently verified at greater than 99% purity using HPLC analysis and mass spectrometry identity confirmation. Testing is performed by an accredited third-party laboratory — not in-house. Batch-specific Certificates of Analysis showing the actual test results for your production lot are available on every individual product page.
Are these peptides approved for human use?
No. All products in this category are sold strictly for laboratory and controlled scientific research purposes only (Research Use Only — RUO). They are not approved by the FDA or any regulatory body for human or veterinary use, are not intended for therapeutic application, and should not be administered to humans or animals under any circumstances. Use is restricted to qualified researchers working within appropriate laboratory settings.
Do you provide bulk/wholesale quantities for GLP-2T and GLP-3R?
Yes. Both GLP-2T and GLP-3R are available in 10-vial bulk kit configurations. GLP-2T bulk kits are available in 20mg and 40mg per vial sizes. GLP-3R bulk kits are available in 10mg, 20mg, 30mg, and 50mg per vial sizes. Bulk kits are designed for research teams requiring consistent compound supply across extended protocols. Each vial in every kit is individually tested and covered by the same batch-level COA documentation as individual vials.
Research Use Only Disclaimer:
All products on this page are sold strictly for laboratory and controlled scientific research purposes only. These compounds are not approved by the FDA or any regulatory authority for human or veterinary use. They are not intended for consumption, therapeutic application, or administration to humans or animals. All use must remain within qualified laboratory research settings. Midnight Sun Peptides assumes no liability for any use outside of controlled research environments.
